The Next MedTech Revolution with Top VC UpFront
Top Venture Investor Fund Upfront Ventures on the Next MedTech Revolution (and Opportunity)
Kevin Zhang, Partner at Upfront Ventures, one of the preeminent U.S. early-stage investment funds, will be in conversation with Jon Medved, Founder and CEO of OurCrowd. You will get insights into Bionaut Labs, whose revolutionary technology optimizes treatment of severe brain disorders. Bionaut delivers brain impenetrable anti-cancer agents such as chemotherapy directly to the site of a tumor using microscale robots, and without systemic toxicity or side effects. Led by a world-class team of medical, engineering, and drug development experts, Bionaut Labs’ is introducing breakthrough technology to the CNS (Central Nervous System) market, which is currently valued at $130 billion. Upfront Ventures manages over $2 billion in total raised funds for early-stage investments in more than 200 companies, with notable exits including Ulta Overture, PayPal Credit, TrueCar, Disney Digital Network, Kyriba and Ring. Partner Kevin Zhang is an interdisciplinary entrepreneur who specializes in solving big problems in healthcare and the life sciences. Prior to joining Upfront in 2012, Kevin worked at Verscend Technologies, a healthcare software startup in Boston, focusing on data analytics product development selling into payers and providers.